Concept

Brain Control

ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor / CROWN: 7-Year Update for Lorlatinib

"Dr Mok emphasized the durability of that protection, pointing to a plateau in brain tumor progression and the development of new brain metastases after 36 months. Ninety-six percent of patients in the lorlatinib group who had no brain metastases at baseline saw no evidence of intracranial tumor progression from 24 months onward, through 84 months. (Patients with early progression had a higher tumor mutation burden compared to long-term responders, he noted.)\n\n“The 7-year CROWN update is very impressive and further supports lorlatinib as a highly active first-line therapy for advanced ALK-positive NSCLC,” commented Dr Schoenfeld. “[T]hese are among the most durable long-term data we have seen in advanced NSCLC. The intracranial control is also particularly important, with no new intracranial progression events reported after 30 months on lorlatinib.”"

Related Ideas

  • Chronic DiseaseASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CROWN: 7-Year Update for Lorlatinib
  • Survival OutcomesASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
  • Study DesignASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
  • Response RatesASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
  • Testing10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 2. Hyrnuo as a First Treatment for HER2-Mutant Lung Cancer
  • TRITON FindingsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy
  • Treatment Findings10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
  • Expert CommentaryASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
Brain Control | ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor | Bifalgorithm | Bifalgorithm